trial

Optimizing CBSST With Executive Function Training for Schizophrenia (R33)

NCTId NCT07658391
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Not Yet Recruiting
Enrollment 106 (estimated)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2029-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Not Yet Recruiting
Enrollment
106 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2026-10-01
Primary completion
2029-06
Eligibility
ALL · 60 Years

Interventions & indications

Drugs
E-CBSSTE-SC

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
University of Texas Southwestern Medical CenterCollaborator

Investigators

2
Eric L. Granholm, PhDPrincipal Investigator
Tarek Rajji, MD, FRCPCPrincipal Investigator

Sites

2 total
San Diego, United StatesDallas, United States

Facts & assertions

4 sourced
Enrollment
106
Phase
NA
Primary Completion Date
2029-06
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
E-CBSST
drug
E-SC
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
University of Texas Southwestern Medical Center
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Eric L. Granholm, PhD
person
Tarek Rajji, MD, FRCPC
person